MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression

Overview

Journal Curr Med Sci

Specialty General Medicine

Date 2023 Oct 12

PMID 37828372

Authors

Cheng Qiu

Yong-Dong Feng

Xi Yang

Affiliations

Soon will be listed here.

Abstract

Objective: Gastrointestinal stromal tumors (GISTs) can rapidly proliferate through angiogenesis. Previous studies indicated the potential influence of microRNA on the progression of tumor immature angiogenesis. This study aimed to explore the specific mechanism by which microRNA-409-5p (miR-409-5p) contributes to GIST.

Methods: To identify genes potentially involved in the development and progression of GIST, the differences of miR-409-5p between tumors and adjacent tissues were first analyzed. Following this analysis, target genes were predicted. To further investigate the function of miRNA in GIST cells, two GIST cell lines (GIST-T1 and GIST882) were transfected with lentiviruses that stably expressed miR-409-5p and scrambled miRNA (negative control). Later, the cells were subjected to Western blotting and ELSA to determine any differences in angiogenesis-related genes.

Results: In GISTs, there was a decrease in the expression levels of miR-409-5p compared to the adjacent tissues. It was observed that the upregulation of miR-409-5p in GIST cell lines effectively inhibited the proteins hypoxia-inducible transcription factor 1β (HIF1β) and vascular endothelial growth factor A (VEGF-A). Further investigations revealed that miR-409-5p acted as an inhibitor of angiogenesis by binding to the 3'-UTR of Lysine-specific demethylase 4D (KDM4D) mRNA. Moreover, the combination of miR-409-5p with imatinib enhanced its inhibitory effect on angiogenesis.

Conclusion: This study demonstrated that the miRNA-409-5p/KDM4D/HIF1β/VEGF-A signaling pathway could serve as a novel target for the development of therapeutic strategies for the treatment of imatinib-resistance in GIST patients.

References

Corless C, Barnett C, Heinrich M . Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011; 11(12):865-78. DOI: 10.1038/nrc3143. View

Miettinen M, Lasota J . Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011; 104(8):865-73. PMC: 7384443. DOI: 10.1002/jso.21945. View

Joensuu H, Hohenberger P, Corless C . Gastrointestinal stromal tumour. Lancet. 2013; 382(9896):973-83. DOI: 10.1016/S0140-6736(13)60106-3. View

Goettsch W, Bos S, Breekveldt-Postma N, Casparie M, Herings R, Hogendoorn P . Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005; 41(18):2868-72. DOI: 10.1016/j.ejca.2005.09.009. View

Roberts P, Eisenberg B . Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2003; 38 Suppl 5:S37-8. DOI: 10.1016/s0959-8049(02)80601-3. View

Demetri G, von Mehren M, Blanke C, Van Den Abbeele A, Eisenberg B, Roberts P . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7):472-80. DOI: 10.1056/NEJMoa020461. View

Blanke C, Demetri G, von Mehren M, Heinrich M, Eisenberg B, Fletcher J . Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4):620-5. DOI: 10.1200/JCO.2007.13.4403. View

Nishida T, Shirao K, Sawaki A, Koseki M, Okamura T, Ohtsu A . Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol. 2008; 13(3):244-51. DOI: 10.1007/s10147-007-0746-y. View

Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen S, Brabec P . Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2011; 13(3):265-74. DOI: 10.1016/S1470-2045(11)70299-6. View

10.

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

11.

Mattick J . The genetic signatures of noncoding RNAs. PLoS Genet. 2009; 5(4):e1000459. PMC: 2667263. DOI: 10.1371/journal.pgen.1000459. View

12.

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

13.

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

14.

Ling H, Fabbri M, Calin G . MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013; 12(11):847-65. PMC: 4548803. DOI: 10.1038/nrd4140. View

15.

Bader A . miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012; 3:120. PMC: 3387671. DOI: 10.3389/fgene.2012.00120. View

16.

Bader A, Brown D, Stoudemire J, Lammers P . Developing therapeutic microRNAs for cancer. Gene Ther. 2011; 18(12):1121-6. PMC: 3910432. DOI: 10.1038/gt.2011.79. View

17.

Chen L, Zheng J, Zhang Y, Yang L, Wang J, Ni J . Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther. 2011; 19(8):1521-8. PMC: 3149175. DOI: 10.1038/mt.2011.64. View

18.

Hartmann P, Zhou Z, Natarelli L, Wei Y, Nazari-Jahantigh M, Zhu M . Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4. Nat Commun. 2016; 7:10521. PMC: 4742841. DOI: 10.1038/ncomms10521. View

19.

Jeon Y, Kim T, Park D, Nuovo G, Rhee S, Joshi P . miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC. Nat Commun. 2018; 9(1):5110. PMC: 6269493. DOI: 10.1038/s41467-018-07561-8. View

20.

Josson S, Gururajan M, Hu P, Shao C, Chu G, Zhau H . miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 2014; 20(17):4636-46. PMC: 4155061. DOI: 10.1158/1078-0432.CCR-14-0305. View